The Scientific World Journal / 2012 / Article / Tab 1

Review Article

Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment

Table 1

Clinical trials of combinations of adhesion inhibitors and chemotherapy for AML.

TitleClinicaltrials.gov designationInstitution or sponsor

Study of plerixafor combined with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemiaNCT00990054Multicenter-Genzyme-Sanofi

First in human study to determine the safety, tolerability, and preliminary effectiveness of MDX-1338 (BMS936564) in subjects with acute myelogenous leukemia (AML)NCT01120457Multicenter-Bristol-Myers Squibb

Granulocyte colony-stimulating factor (G-CSF) and plerixafor plus sorafenib for acute myelogenous leukemia (AML) with FLT3 mutationsNCT00943943MD Anderson Cancer Center

Chemosensitization with plerixafor plus G-CSF in acute myeloid leukemiaNCT00906945Washington University

IV plerixafor with mitoxantrone etoposide and cytarabine for acute myeloid leukemia (AML)NCT01027923Washington University

Plerixafor and clofarabine in frontline treatment of elderly patients with acute myelogenous leukemia (AML)NCT01160354MD Anderson Cancer Center

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.